Biotechnology company Mesoblast (ASX:MSB) said its cash balance as of Sept. 30 stood at $51.1 million, with a further $60 million available from existing financing facilities on the approval of Ryoncil, a treatment candidate for children with steroid-refractory acute graft-versus-host disease, according to a Thursday filing with the Australian Securities Exchange.
The fiscal first quarter saw a net operating cash spend of $10.5 million, a 26% reduction from the same period last year, the filing said.
In the September quarter, the company filed a biologics license application with the US Food and Drug Administration for Ryoncil and expects a decision on or before Jan. 7, 2025, according to the filing.
Shares fell nearly 2% in morning trade Friday.
Price (AUD): $1.30, Change: $-0.03, Percent Change: -1.89%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。